Bank of America Boosts Hims & Hers Health (NYSE:HIMS) Price Target to $23.00

Hims & Hers Health (NYSE:HIMS) had its price target upped by Bank of America from $20.00 to $23.00 in a report published on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also issued reports on HIMS. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. TD Cowen boosted their price target on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Piper Sandler restated a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Truist Financial lifted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Finally, Jefferies Financial Group upped their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and an average target price of $20.07.

Hims & Hers Health Stock Down 1.9 %

Hims & Hers Health stock opened at $22.36 on Monday. The company’s 50-day moving average price is $16.70 and its 200-day moving average price is $17.50. The company has a market cap of $4.80 billion, a PE ratio of -2,236.00 and a beta of 1.06. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm’s revenue was up 51.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.03) EPS. As a group, sell-side analysts expect that Hims & Hers Health will post 0.22 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 2,054 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $22.00, for a total transaction of $45,188.00. Following the sale, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the sale, the chief financial officer now directly owns 145,763 shares in the company, valued at $2,960,446.53. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 835,911 shares of company stock valued at $14,640,096 in the last 90 days. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. CWM LLC lifted its holdings in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Arizona State Retirement System lifted its stake in Hims & Hers Health by 3.0% in the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after buying an additional 1,173 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Hims & Hers Health by 6.6% in the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after buying an additional 1,212 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares in the last quarter. Finally, Swiss National Bank raised its holdings in shares of Hims & Hers Health by 0.7% during the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after acquiring an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.